Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its manufacturing facility in a major bid to save cash.

An oral small molecule from New York-based biotech Oligomerix curbed the tangling of tau protein in the brains of mice that ...

With its FDA-approved neurostimulator implant aimed at helping patients recover from stroke, MicroTransponder has raised $65 ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Lila Sciences is looking to use $200 million in seed funding to develop advanced AI that can power fully autonomous research ...

Synthetic biology specialist GRO Biosciences started exploring strategic alternatives about six months after raising a series ...

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...

Gilead’s Sandra Patterson has “decided to leave the company” after two years in the SVP corporate controller and chief ...

The National Institutes of Health (NIH) is continuing its grant-canceling spree, allegedly targeting dozens of research ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...